Aflac Incorporated (AFL) 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers Aflac Incorporated's Form 10-K for the fiscal year ended December 31, 2024. Aflac is a leading provider of supplemental health and life insurance products, primarily operating in Japan and the United States. The Company's strategy focuses on providing financial protection for medical events not covered by primary insurance, utilizing a strong brand (the Aflac Duck) and diverse distribution channels including agents, brokers, and strategic alliances (e.g., Japan Post Group).
Key Financial Metrics (2024 vs. 2023)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $18.9 billion | $18.7 billion | +1.2% |
| Net Earnings | $5.4 billion ($9.63 diluted EPS) | $4.7 billion ($7.78 diluted EPS) | +16.8% |
| Adjusted Earnings | $4.1 billion ($7.21 diluted EPS) | $3.7 billion ($6.23 diluted EPS) | +11.0% |
| Net Investment Gains | $1.3 billion | $0.6 billion | +115% |
| Shareholders' Equity | $26.1 billion | $22.0 billion | +18.6% |
| Adjusted Book Value (excl. AOCI) | $29.1 billion ($52.87/share) | $27.5 billion ($47.55/share) | +5.8% |
| Return on Average Equity | 22.6% | 22.1% | +0.5 pts |
| Dividends Paid | $2.00 per share | $1.68 per share | +19.0% |
Note: Adjusted earnings exclude items outside management's control, such as net investment gains/losses and foreign currency translation impacts.
Material Changes and Segment Performance
- Foreign Currency Impact: The average yen/dollar exchange rate weakened to 150.97 in 2024 (from 140.57 in 2023), negatively impacting reported earnings by approximately $0.18 per diluted share. However, the weakening yen increased the yen value of U.S. dollar-denominated investment income.
- Aflac Japan:
- Pretax adjusted earnings increased 8.0% to $3.5 billion.
- Net earned premiums decreased 13.9% in dollars (6.9% in yen) due to internal reinsurance transactions and limited-pay products reaching paid-up status.
- Benefit ratio improved to 62.5% (from 66.0%) driven by reserve remeasurement gains.
- New annualized premium sales increased 5.6% in yen, driven by the launch of the "Tsumitasu" life insurance product.
- Aflac U.S.:
- Pretax adjusted earnings decreased 5.5% to $1.4 billion.
- Net earned premiums increased 2.7% to $5.8 billion.
- Benefit ratio increased to 46.8% (from 42.8%) due to lower reserve remeasurement gains and higher incurred claims.
- New annualized premium sales decreased 1.0% to $1.5 billion, reflecting a focus on profitable growth and softer dental sales.
- Investments: Net investment gains of $1.3 billion included $1.1 billion from derivative and foreign currency activities and $259 million from sales/redemptions. Credit loss allowances increased by $256 million.
Guidance, Outlook, and Risks
- 2025 Outlook:
- Aflac Japan: Expects benefit ratios of 64%-66% and expense ratios of 20%-23%. For 2025 specifically, benefit ratios are expected toward the higher end and expense ratios toward the lower end.
- Aflac U.S.: Expects benefit ratios of 48%-52% and expense ratios of 36%-39%. For 2025, benefit ratios are expected toward the lower end and expense ratios toward the higher end.
- Capital Deployment: The Board announced a 16.0% increase in the quarterly cash dividend effective Q1 2025. The Company maintains a target Economic Solvency Ratio (ESR) of 170%-230% for Japan and a combined Risk-Based Capital (RBC) ratio of 350%-450% for the U.S.
- Key Risks:
- Interest Rate Risk: Significant exposure to interest rate fluctuations affecting investment portfolio values and liability valuations. Rising rates decrease fixed maturity values but reduce liability values.
- Foreign Exchange Risk: Continued volatility in the yen/dollar exchange rate significantly impacts reported financial results and regulatory capital.
- Investment Credit Risk: Exposure to commercial real estate and highly leveraged companies; potential for credit downgrades and defaults in a high-interest-rate environment.
- Regulatory Changes: Introduction of the Insurance Capital Standards (ICS) in Japan effective 2025 and ongoing U.S. regulatory examinations.
Investor Verification Checklist
- Verify Currency Sensitivity: Confirm the impact of the yen/dollar exchange rate on future earnings, as a significant portion of revenue is translated from yen.
- Review Investment Portfolio Quality: Assess the exposure to commercial real estate (specifically office properties) and the adequacy of credit loss allowances given the high-interest-rate environment.
- Monitor Regulatory Capital Ratios: Track the Solvency Margin Ratio (SMR) in Japan and Risk-Based Capital (RBC) in the U.S. to ensure compliance with regulatory thresholds and dividend capacity.
- Assess Sales Trends: Evaluate the sustainability of new annualized premium sales growth in Japan (driven by new products) versus the decline in the U.S. (driven by strategic focus on profitability).
- Check Dividend Capacity: Verify the ability of subsidiaries (particularly Aflac Japan) to remit dividends to the Parent Company under current regulatory and solvency constraints.